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Abstract
Background: Despite the limited success after decades of intensive research and development efforts, vaccination
still represents the most promising strategy to significantly reduce the disease burden in malaria endemic regions.
Besides the ultimate goal of inducing sterile protection in vaccinated individuals, the prevention of transmission by
so-called transmission blocking vaccines (TBVs) is being regarded as an important feature of an efficient malaria
eradication strategy. Recently, Plasmodium falciparum GAP50 (PfGAP50), a 44.6 kDa transmembrane protein that
forms an essential part of the invasion machinery (glideosome) multi-protein complex, has been proposed as novel
potential transmission-blocking candidate. Plant-based expression systems combine the advantages of eukaryotic
expression with a up-scaling potential and a good product safety profile suitable for vaccine production. In this
study we investigated the feasibility to use the transient plant expression to produce PfGAP50 suitable for the
induction of parasite specific inhibitory antibodies.
Results: We performed the transient expression of recombinant PfGAP50 in Nicotiana benthamiana leaves using
endoplasmatic reticulum (ER) and plastid targeting. After IMAC-purification the protein yield and integrity was
investigated by SDS-PAGE and Western Blot. Rabbit immune IgG derived by the immunization with the plastid-
targeted variant of PfGAP50 was analyzed by immune fluorescence assay (IFA) and zygote inhibition assay (ZIA).
PfGAP50 could be produced in both subcellular compartments at different yields IMAC (Immobilized Metal Affinity
Chromatography) purification from extract yielded up to 4.1 μg/g recombinant protein per fresh leaf material for
ER-retarded and16.2 μg/g recombinant protein per fresh leave material for plasmid targeted PfGAP50, respectively.
IgG from rabbit sera generated by immunization with the recombinant protein specifically recognized different
parasite stages in immunofluorescence assay. Furthermore up to 55 % inhibition in an in vitro zygote inhibition
assay could be achieved using PfGAP50-specific rabbit immune IgG.
Conclusions: The results of this study demonstrate that the plant-produced PfGAP50 is functional regarding the
presentation of inhibitory epitopes and could be considered as component of a transmission-blocking malaria
vaccine formulation.
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Background
Still affecting millions of people around the world, pre-
dominantly in developing countries [1], malaria is one of
the most relevant poverty-related infectious tropical dis-
eases. Even though prophylactic and therapeutic agents ex-
ists, they are not broadly available and affordable for the
local populations. Measures of vector elimination and con-
trol by draining mosquito breeding pools, application of in-
secticides, and bed nets have not been sufficiently effective
in many cases. Additionally, increasing resistances of the
parasite and the vector against both, chemical control mea-
sures and medical treatments are a growing problem [2, 3].
Therefore, the availability of a vaccine is being regarded as
an essential component of a successful malaria eradication
strategy [4]. Despite intense research efforts no vaccine
that provides robust sterile protection against malaria is
available today. Involving two different hosts, mosquito
and man, the life cycle of P. falciparum is complex and fea-
tures three different stages. As summarized in the WHO
rainbow table [5], the majority of proteins used in the con-
text of malaria vaccine candidates today and in the past,
are either pre-erythrocytic, or blood stage antigens like
PfCSP [6], proteins from the merozoite surface protein
family (PfMSPn) [7], PfAMA1 [8] and other blood stage
surface proteins [9]. After successful completion of clinical
trials GSK’s circumsporozoite protein (CSP)-based pre-
erythrocytic stage vaccine Mosquirix® [10] received a posi-
tive opinion from EMA and is expected to enter the
market soon, following WHO recommendation and clear-
ance by respective national regulators. Even though being
by far the most advanced malaria vaccine, the impact of
Mosquirix® is expected to be limited by moderate efficacy
(only up to 60–70 % of the vaccinees protected) and rela-
tively short-lived protection [11]. Besides vaccines targeting
the pre-erythrocytic stage of the parasite and therefore
aiming at the induction of sterile protection by preventing
the initial establishment of the infection, there are at least
two other types of vaccines. Blood stage vaccines could be
useful to suppress manifestation of clinical symptoms
caused by high parasite load in the blood of the patients,
while so called transmission blocking vaccinestarget the
sexual stages of the parasite to prevent proliferation in, or
trafficking through the mosquito and thereby inhibit the
transmission of the parasites from infected to healthy indi-
viduals. In the context of malaria eradication efforts and
after a recent update of the Malaria Vaccine Technology
Roadmap in 2013 [12], transmission-blocking vaccines
have recently received elevated attention. The first and
most advanced transmission-blocking malaria vaccine can-
didate is Pfs25, a 24 kDa post-fertilization macrogamete/
zygote surface antigen featuring four epidermal growth fac-
tor (EGF)-like domains [13, 14]. It has been shown in dif-
ferent studies that immunization with recombinant Pfs25
induces antibodies with strong transmission-blocking
activity [15–18]. Being exclusively expressed in parasite
stages that develop after fertilization within the mos-
quito and thereby being naturally not exposed to the
human immune system the highly conserved Pfs25
represents an excellent target for vaccine induced
transmission-blocking antibody responses. Other potentially
transmission-blocking vaccine candidates in development
are the pre-fertilization gamete/gametocyte antigens Pfs230
and Pfs48/45. In contrast to Pfs25 these proteins have been
shown to be targets of natural immune responses [19] since
they are already expressed on gametocytes that (within in-
fected erythrocytes) occur in the human host.
PfGAP50, a 44.6 kDa transmembrane protein, forms
an essential part of the actin-myosin motor complex
driven invasion machinery (glideosome) associated to
the multi-protein complex called inner membrane com-
plex (IMC) [20–23]. Detailed investigations on the role
of PfGAP50 during sexual stage development presented
by Simon et al. [24] indicate that the protein relocates
from the IMC to the plasma membrane during gameto-
cyte activation and gametocyte egress from erythrocytes
triggered by change of temperature, pH and presence of
xanthurenic acid encountered within the mosquito mid-
gut after a blood meal. Since in this work it has also
been shown that PfGAP50 may protect the gametes
from complement-mediated lysis by binding the human
complement Factor H, the protein can be regarded as
novel transmission-blocking candidate.
Plant-based transient expression systems are robust,
fast and scalable platforms capable of oxidative folding,
assembly of multimeric proteins and high level expres-
sion [25]. Several pharmaceutically relevant proteins like
monoclonal antibodies [26], therapeutic enzymes [27] as
well as antigens, including malaria vaccine candidates
[28–33] have been produced successfully by transient
plant expression. The Agrobacterium tumefaciens transi-
ent plant expression system offers the chance to com-
pare the efficiency of recombinant protein expression in
various subcellular compartments (ER, cytoplasm, plas-
tids) with different features regarding oxidative folding
or post-translational modifications [34, 35].
Here, we report the successful plant-based production
and characterization of the novel TBV candidate
PfGAP50. The plastid targeted PfGAP50 was obtained at
high quality by one-step IMAC purification and used for
the immunization of rabbits. The resulting rabbit im-
mune IgG preparations were used in different in vitro
assays to confirm the induction of antibodies that
recognize PfGAP50 in the native context.
Results
Cloning the PfGAP50 expression constructs
The cDNA coding for the extracellular domain of
PfGAP50 (Fig. 1a) was cloned into the binary plant
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expression vectors pTRAkc-ERH and pTRAkc-cTPH. For
the cloning we used cDNA encoding amino acids Q26 to
R369 featuring the PfGAP50 without the native N-terminal
signal peptide (to be replaced by the plant-specific target-
ing signals) and without the transmembrane domain to en-
hance the solubilty of the protein targeted to either the ER
or plastid. The resulting pTRAkc-GAP50-ERH (Fig. 1b)
construct features sequences for an N-terminal signal pep-
tide (for targeting the protein to the secretory pathway),
and a C-terminal His6-tag (for affinity purification and
detection) followed by a SEKDEL ER-retrieval signal (for
ER-retention). The second expression construct pTRAkc-
GAP50-cTPH (Fig. 1b) provides an N-terminal chloroplast
targeting peptide and a C-terminal His6-tag.
Transient expression and purification of PfGAP50 in N.
benthamiana
Both expression constructs were used for transient plant
expression of PfGAP50. The recombinant protein was
purified by IMAC from plant extracts prepared from in-
filtrated N. benthamiana leaves 5 days post-infiltration
(dpi). The experiment was repeated independently three
times for both constructs and a mock purification using
wild type material was carried out once to simplify the
identification of potential contaminants. Figure 2a and b
exemplarily show the SDS-PAGE and immunoblot ana-
lysis of one experiment per construct (SDS-PAGE fea-
turing the samples from all replicates is shown in
additional file 1). The simple one-step purification pro-
cedure using three step elution (10 mM, 100 mM and
250 mM) yielded PfGAP50 proteins at different levels of
purity and high integrity. As shown in Fig. 2a and b, elu-
tion at 10 mM Imidazole only yielded few host cell pro-
teins (to a large proportion presumably the large subunit
of Ribulose-1,5-bisphosphat-carboxylase/-oxygenase (Ru-
BisCo), 56 kDa) and no detectable PfGAP50-ERH or
PfGAP50-cTPH (as shown by His6-specific immuno-
blot), at 100 nM we detected host cell proteins at higher
abundance as well as detectable amounts of target pro-
teins. The elution fraction E3 (250 mM Imidazole) in
both cases contained the highest amount of PfGAP50
and one major host cell protein band running at the size
of the large subunit of RuBisCo. Yields were determined
by densitometric analysis of SDS-PAGE lanes containing
the E3 fractions against a BSA standard curve derived
from 4 different concentrations of BSA. The clear differ-
ences in yield between the ER-retarded and the
chloroplast-targeted variant of the protein were observed
in several other experiments (data not shown). Figure 2c
shows the average E3 yields obtained after three expres-
sion and purification experiments of PfGAP50-cTPH
(16.2 ± 1.8 μg/g fresh leaf weight (FLW), 7 g leaf material
for each repeat) and PfGAP50-ERH (4.1 ± 0.98 μg/g
FLW, 4.5 g leaf material for each repeat). The differences
are statistically significant P = 0.0005. The higher accu-
mulation levels of intact PfGAP50 also correlated with
the achieved relative abundance calculated by densito-
metric analysis of SDS-PAGE image (Additional file 1)
for each purification experiment. For both PfGAP50 var-
iants (PfGAP50-cTPH and PfGAP50-ERH) the highest
purity was obtained in the third elution step (E3 frac-
tion) at 250 mM imidazole, while the previous step at
100 mM imidazole still contained a number of host cell
proteins, presumably the large subunit of the RuBisCo
together with the recombinant protein. This protein was
also present as the major contamination in the E3 frac-
tion. In E3 PfGAP50-cTPH was obtained at a relative
abundance of 73 % ± 8.5 while PfGAP50-ERH was less
pure (32.3 % ± 3.1). The corresponding E3 fraction from
an up-scaled infiltration experiment (PfGAP50-cTPH)
was used for the immunization of rabbits as described in
the methods section.
Determination of antigen-specific titers
To initially assess the immunogenicity and parasite inhibi-
tory efficacy of the recombinant PfGAP50-cTPH, two
rabbits were immunized using a hyper immunization
protocol. Endpoint IgG titers against PfGAP50 were deter-
mined in serum samples taken on days 0, 35, 63 and 91 as
Fig. 1 Gene IDs and plant expression cassettes. a Names, accession
numbers and amino acid sequence range of PfGAP50 (for further
details refer to the methods section). b Schematic drawing of the
expression cassettes in the plant binary expression vector pTRAkc
(not to scale). SAR: scaffold attachment region; P35SS: Cauliflower
mosaic virus 35S promoter with duplicated 35S enhancer region;
CHS 5ʹ UTR: 5ʹ untranslated region of the Petroselinum crispum
chalcone synthase gene; SP: transit peptide sequence of the murine
antibody 24 heavy chain [60]; TP: chloroplast targeting signal from
small subunit of RuBisCO from Solanum tuberosum; GAP50: PfGAP50;
His6-tag: six histidine tag for IMAC purification; SEKDEL: ER-retention
signal. pA35S: Cauliflower mosaic virus 35S polyadenylation signal.
Relevant restriction sites are indicated
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described in the methods section. As shown in Fig. 3, the
resulting titers are moderate for both rabbits with a max-
imum antibody titer observed after day 63 with 1:2.6 x 104
for rabbit number two. The titers did not increase after
subsequent boosts.
Immunofluorescence assay
An IFA was used to determine the reactivity of PfGAP50-
specific rabbit immune IgG against P. falciparum schiz-
onts, gametocytes and gametes. As shown in Fig. 4, rabbit
antibodies raised against PfGAP50 specifically labeled the
surfaces of the three different stages. Co-labeling with
mouse antibodies against PfMSP1 and Pfs25 was used for
stage-specific counterstaining. No fluorescence signal was
Fig. 2 SDS-PAGE/immunoblot analysis of plant produced PfGAP50. a:
Purification of plastid-targeted PfGAP50 (PfGAP50-cTPH). For purification,
7.0 g infiltrated leaf material were used. Reducing SDS-PAGE (left panel)
and immunoblot (right panel). b: Purification of ER-retarded PfGAP50
(PfGAP50-ERH). For purification, 4.5 g infiltrated leaf material were used.
Reducing SDS-PAGE (left panel) and immunoblot (right panel). M:
Prestained protein marker (Page Ruler Fermentas), 1: 3 μL load (plant
extract), 2: 3 μL flow-through, 3: 6 μL elution step 1 (10 mM imidazole),
4: 6 μL elution step 2 (100 mM imidazole), 5: 6 μL elution step 3
(250 mM imidazole). Western blot was detected with rabbit anti-His6
serum and alkaline phosphatase labeled goat anti rabbit serum. c: Plot
of mean values and standard deviation of the yields for finally purified
(E3) PfGAP50-cTPH and PfGAP50-ERH, determined by densitometric
analysis (against BSA equivalents) of SDS-PAGE from three independent
replicates (SDS-PAGE shown in additional file 1)
Fig. 3 PfGAP50-specific titers in rabbit immune sera. Immune sera
were analyzed by direct ELISA after the first (day 35), the second
(day 63) and third boost (day 91). The threshold for titer definition
was twofold the background signal obtained from the pre-immune
sera. R1: rabbit 1, R2: rabbit 2
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observed when NRS was used for immunolabeling in con-
trol experiments.
Zygote inhibition assay (ZIA)
The ability of PfGAP50-specific rabbit immune IgG to
inhibit zygote development was measured using a ZIA.
As shown in Fig. 5, we observed up to 55 % zygote in-
hibition activity when using 1 mg/mL of the purified
rabbit IgG (bleed2, day 63 and bleed 3, day 91 from both
rabbits, R1 and R2, respectively).
Discussion
Mosquirix (RTS’S), a pre-erythrocytic malaria vaccine
candidate based on PfCSP presented on the surface of
Hepatitis B virus-like particles is now approaching final
regulatory approval. Anyhow, data from the respective
clinical trials indicate that this vaccine will not match
the efficacy and the sustainability of vaccines against
other infectious diseases and suggests further efforts to-
wards improved malaria vaccine formulations eventually
featuring additional antigens from the blood and the
sexual stages of the parasite to introduce functional-
ities that complement the strategy of inducing sterile
protection by immune responses against pre-erythrocytic
antigens. In this context a vaccine component that
provides transmission blocking activity is being
regarded as a valuable contribution to the goal of
malaria eradication.
Here, we describe the transient plant-based production
and characterization of PfGAP50 as transmission-blocking
vaccine candidate antigen. We have used the A. tumefa-
ciens-based transient plant expression platform successfully
in previous studies for the expression and characterization
of different P. falciparum antigens from the pre-
erythrocytic, the blood and the sexual stage as single pro-
teins [28] or as fusions [33, 36]. Along this line, and driven
by the overall vision of implementing this platform for the
rapid and cost efficient production of vaccine antigens in
the context of malaria vaccine R&D and finally even clin-
ical material, we were interested to evaluate the feasibility
to use the transient plant-based expression to produce
Fig. 4 Indirect immunofluorescence assays demonstrating the
reactivity of PfGAP50 specific rabbit immune IgG against different
stage P. falciparum parasites. IFAs were performed on schizonts,
gametocytes and gametes, using PfGAP50 specific rabbit immune
IgG or IgG purified from neutral rabbit serum (NRS) as a negative
control. Mouse anti-Pfs25 and anti-PfMSP1 antibodies were used to
co-label the sexual-stage (Pfs25) and blood stage (PfMSP1) parasites,
respectively. Mouse antibodies were visualized with Alexa Fluor 488-
conjugated secondary antibodies (green) and rabbit antibodies with
Alexa Fluor 594-conjugated secondary antibodies (red). Bar = 5 μm
Fig. 5 Zygote inhibition assay (ZIA) with PfGAP50 specific rabbit
immune IgG. The transmission-blocking potential of the PfGAP50-
cTPH specific rabbit immune IgG (rabbit 1 (R1) and rabbit 2 (R2))
from 2nd (day 63) and 3rd bleed (day 91) was assessed in a ZIA
experiment in comparison with IgG purified from neutral rabbit
serum (NRS) as a negative control. Inhibition was calculated as the
reciprocal value of zygote numbers in comparison with the negative
control. Error bars were derived by generating mean and SD of the
values obtained for immune IgG from the two individual rabbits
using data from three technical replicates
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PfGAP50 suitable for the induction of parasite-specific in-
hibitory antibodies.
Bosch et al. [37] have produced folded, soluble PfGAP50
in the cytosol of E. coli for structural studies. These results
indicate that PfGAP50 may not depend on an oxidative
environment like the plant endoplasmatic reticulum (ER)
for correct folding. Therefore, making use of the possibil-
ity to easily address different subcellular compartments
within the plants, we generated two expression constructs
featuring PfGAP50, one ER-retarded and the other one
targeted to the plastids. Even though plastids lack oxida-
tive conditions and the complex, chaperon-based folding
machinery of the secretory pathway constituted by the ER
and the Golgi apparatus, high-level expression of recom-
binant proteins has been achieved in plastids for several
examples with transient, targeting-based [35, 38, 39] and
stable, transplastomic approaches [40].
In our study we observed significantly higher yields for
recombinant PfGAP50 (±16.2 ± 1.9 μg/g FLW) targeted to
the plastids when compared to PfGAP50 (±4.1 ± 0.98 μg/g
FLW) accumulated in the ER. These values were calcu-
lated by quantification of the finalmaterial (partially puri-
fied by IMAC) and related to yield after extraction and
purification. The differences in achieved purities (73 % ±
8.5 for PfGAP50-cTPH and 32.3 % ± 3.1 for PfGAP50-
ERH) resulted from a constant amount (around 1-2 μg/g
FWL) of a predominant co-purified host cell protein (pre-
sumably the large subunit of RuBisCo).
The observation that a 4-fold higher yield could be
achieved by chloroplast targeting compared to the ER-
retarded version of PfGAP50 was not predictable, but in-
dicates that this strategy should be generally considered
when using plant expression systems for the production
of recombinant proteins at optimal yields. In a study on
the transient and stable plant-based expression of differ-
ent HIV-I antigen constructs Meyers et al. [41] also
compared ER-retardation with chloroplast targeting and
found large protein-specific differences in yields, includ-
ing up to 20-fold higher (HIV-I p17/p24) or 4-fold lower
yields (HIV-I p24), by chloroplast targeting compared to
ER-retardation. These results also emphasize the versa-
tility of the transient plant expression system as a tool in
vaccine candidate development and evaluation, since dif-
ferent properties and requirements of heterologous pro-
teins like vaccine candidate antigens can be addressed
by simply testing the respective proteins in the context
of different subcellular targeting options.
The yields of 16 and 4 μg/g FLW were calculated for
comparative purposes only considering the PfGAP50
amounts found in the elution fraction E3. Since it is obvi-
ous that also the fraction E2 contains relevant amounts of
PfGAP50 (especially for PfGAP50-cTPH, where E2 seems
to contains at least the same amount as E3) it can be spec-
ulated that by developing a more advanced extraction and
purification strategy [42, 43] it should be possible to sig-
nificantly increase the yield of PfGAP50-cTPH towards
levels of 30-50 μg/g FLW. These assumptions can be used
to briefly asses the question of economic perspectives of
the production of this transmission-blocking vaccine can-
didate by transient expression in plants. As basis for this
estimation one can refer to the numbers provided by Tusé
et al. [44] in an article about the manufacturing economics
of plant-made biologics. In this context the per/dose pro-
duction costs (upstream) for a recombinant butyrylcholin-
esterase manufactured by transient plant-based expression
for therapeutic purposes were calculated as 474 $ (produc-
tion costs upstream) per dose based on the following vari-
ables (Facility capacity: 25 kg recombinant protein/year at
expression levels of 500 μg/g, Overall Yield: 100 μg/g
FLW, 1 dose: 400 mg). Adapting this calculation to a
25 μg dose, the per/dose production costs for PfGAP50 at
an overall yield of 50 μg/g would be 0.06 $ or 0.19 $ at an
overall yield (as observed in this study under pre-process
development conditions) of 16 μg/g at a capacity of 32
000 000–100 000 000 doses per year. These numbers can
be combined with previously calculated numbers pre-
sented by [45] assuming that downstream costs will typic-
ally account for around 80 % of the total production costs.
For the PfGAP50 scenario this would mean between 0.30
$ (yield 50 μg/g) and 0.95 $ (yield 16 μg/g). With these
total production costs it should be possible to match a
vaccine price that would provide cost effectiveness in a
malaria endemic region, given a sufficient efficacy of the
vaccine. Based on models [46] and empirical data [47] the
cost effectiveness of a pre-erythrocytic vaccine (for the
model) and more specifically RTS,S (within a trial setting)
has been calculated. These complex calculations do rely
on a large number of factors, including efficacy, transmis-
sion rate, and look at the socio-economic impact of mild,
as well as severe infections and therefore should be
regarded as a very rough estimate, when being transferred
to another scenario. Anyhow, together with the results
from another modeling approach that also involves trans-
mission blocking vaccines [48] it seems reasonable to as-
sume cost effectiveness of a decent transmission blocking
vaccine at a vaccine price somewhere between 2 and 10 $,
and therefore roughly 10-times higher than the assumed
total production costs for PfGAP50 derived from a calcu-
lation that was working with a production facility able to
produce 32 000 000 to 100 000 000 doses per year.
Because of the better yields and higher purity,
the plastid-targeted PfGAP50-cTPH was chosen
for rabbit immunization studies. Using a standard
hyper immunization protocol moderate titers below
1:1x105were observed in both rabbits. In contrast to other
rabbit immunizations we conducted with plant-produced
P. falciparum antigens under the same conditions [28, 36],
in this study we did not observe an increase of antigen-
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specific titers after the second and/or the third boost. In
contrast, for rabbit R1 the titers even slightly decreased
over the course of the immunization period. There are dif-
ferent possible explanations for this somehow unexpected
result (e.g. lack of suitable T-helper epitopes, immune sup-
pressive activity, influences of animal housing condi-
tions) but given the low number of animals (two)
used in this study the observation should probably
not be overestimated.
The ability of PfGAP50-cTPH-specific rabbit IgG to
recognize PfGAP50 in its native context was assessed by
immunofluorescence assays. In these experiments, a
staining of blood stage (schizonts) as well as sexual stage
parasites (gametocytes and gametes) was observed. Be-
cause in schizonts and gametocytes before activation the
PfGAP50 is part of the actin-myosin motor complex
driven invasion machinery (glideosome) associated to
the multi-protein complex called inner membrane com-
plex (IMC), the cell membranes were permeabilized by
saponin washing upon preparation of these samples.
These results correlate well with what has been observed
by Simon et al. [24] after mouse immunization studies
performed with recombinant PfGAP50-GST fusions pro-
duced in E. coli and confirm that properly folded PfGAP50
could be produced by transient plant-based expression.
To initially investigate the parasite inhibitory and
thereby transmission-blocking potential of the PfGAP50-
cTPH-specific antibodies a zygote inhibition assay was
performed by the addition of PfGAP50-cTPH-specific
rabbit immune IgG to gametocyte cultures. The ob-
served reduction of zygote numbers after 16 h of incuba-
tion between 37 % and 55 % is in good accordance with
the 44 % reduction observed by Simon et al. [24] with
PfGAP50-specific murine antibodies, providing another
indication that the plant-produced PfGAP50 is functional
regarding the presentation of inhibitory epitopes and is
generally suitable as component of a transmission-
blocking malaria vaccine formulation.
Taken together the results encourage the investigation
of chloroplast targeting for other malaria vaccine con-
structs using the transient expression system. This would
be especially interesting for antigens like Pfs25, PfAMA1,
PfMSP3 or others that contain potential N-linked glyco-
sylation sites which are not post-translationally modified
in the native context because Plasmodium lacks the mo-
lecular machinery for N-linked glycosylation [49]. In most
cases when potentially N-glycosylated P.falciparum anti-
gens are produced in eukaryotic expression hosts N-
glycosylation is being prevented by mutation of the NxT/S
motifs in the amino acid sequence of the proteins [50].
Another option that has been applied for the generation
of diversity covering variants of PfAMA1 [51] is the iden-
tification of allelic variations that do not contain the
motive at a respective site, allowing to use a native
P.falciparum sequence instead of an artificial one resulting
from the introduced mutation of the N or the T/S residue.
Using chloroplast targeting, it is possible to express the
fully native, non-glycosylated protein sequence in an en-
vironment that is suitable for the expression of at least
some folded proteins as already shown for the expression
of the disulfide-rich P.falciparum sexual stage vaccine an-
tigens Pfs25 and Pfs28 in the chloroplasts of the
eukaryotic green microalgae, Chlamydomonas reinhardtii
by Gregory et al. [52]. Another advantage of chloroplast
targeting is the option to attach the recombinant antigens
to starch granules by fusion to the granule bound starch
synthase (GBSS), which enables the presentation of the
antigen in the context of starch granules offering alterna-
tive purification strategies as well as potentially improved
immunogenicity by the particulate format. This concept
has been successfully proven with Plasmodium berghei
and Plasmodium falciparum antigens expressed in a
starch granule bound format in C. reinhardtii by Dauvillée
et al. [53] and also the high immunogenicity of RTS,S the
clinically most advanced malaria vaccine candidate based
on the presentation of the pre-erythrocytic antigen PfCSP
on the surface of hepatitis B virus S antigen (HBs Ag)
based virus like particles, suggests the presentation of mal-
aria antigens in a particulate format. In this context it
should be also mentioned that plants also offer the possi-
bility to express virus like particles from plant virus coat
protein fusion proteins [54].
Conclusion
The results of this study demonstrate that PfGAP50 can be
successfully produced in plants by transient transfection,
and that significantly higher levels can be obtained by
chloroplast targeting. The plant-produced PfGAP50 is
functional regarding the presentation of inhibitory epi-
topes, can be used to induce parasite inhibitory antibodies
and therefore should be considered as an interesting com-
ponent of a transmission-blocking malaria vaccine formu-
lation. Based on these promising results, we will focus on
further optimizing the protein expression and purification
as well as on strategies to improve the immunogenicity of
the recombinant protein or its formulation before proceed-
ing towards more detailed studies involving more animals
and additional, more detailed, functional characterization
of the protein itself as well as corresponding immune IgG
in different parasite inhibition assays.
Methods
Bacteria, plants and parasites
Agrobacterium tumefaciens strain GV3101 : : pMP90RK
[GmR, KmR, RifR] [55] and Nicotiana benthamiana
plants were used for the production of the recombinant
protein by agroinfiltration. Freshly prepared P. falciparum
parasites strain NF54 were used for immunofluorescence
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assay (IFA) and zygote inhibition assay (ZIA) procedures.
P. falciparum parasites were cultivated as previously de-
scribed [56].
Plant expression constructs
The cDNAs encoding the P. falciparum strain 3D7
PfGAP50 extracellular domain without the signal peptide
and GPI-anchor sequence was obtained as synthetic gene,
codon-optimized for N. benthamiana from GeneArt (Life-
Technologies, Darmstadt, Germany). The PfGAP50 se-
quence was introduced via NcoI/NotI cloning either into
the binary vector pTRAkc-ERH [57] between the signal
peptide sequence and a His6-tag followed by the SEKDEL
signal for endoplasmic reticulum (ER) retention [58] or
into pTRAkc-cTPH, a modified variant of the binary vector
pTRAk-(rbcs)cTP [59] between a plastid targeting signal
sequence and a His6-tag (H). The resulting plasmids were
named pTRAkc-GAP50-cTPH and pTRAkc-GAP50-ERH.
All cloning steps were verified by DNA sequencing.
Transient expression in N. benthamiana
The pTRAkc-GAP50-cTPH and pTRAkc-GAP50-ERH
vector were introduced into A. tumefaciens by electropor-
ation using a Multiporator (Eppendorf AG, Hamburg,
Germany) according to the manufacturer’s instructions.
Recombinant A. tumefaciens carrying pTRAkc-GAP50-
cTPH or pTRAkc-GAP50-ERH were used for the transient
expression of PfGAP50 either as ER-retarded or as chloro-
plast targeted variant. Detailed cultivation and infiltration
procedures have been reported elsewhere [28, 31, 33].
Extraction of total soluble protein from N. benthamiana
leaves
The infiltrated N. benthamiana leaves were harvested
5 days post infiltration (dpi) and total soluble protein
was extracted as previously described [33].
Immobilized metal affinity chromatography purification
(IMAC)
After pH adjustment, the clarified extract was loaded onto
a disposable column filled with 1 ml of Ni2+-charged
Chelating Sepharose (GE Healthcare, Solingen, Germany).
After washing with PBS (10 column volumes), bound pro-
teins were eluted in a three-step gradient using PBS con-
taining 10 mM, 100 mM and 250 mM imidazole.
SDS-PAGE and immunoblot analysis
SDS-PAGE and immunoblot analysis was performed
as previously described [33]. The PfGAP50 variants
(PfGAP50-ERH: ER-retarded and PfGAP50-cTPH
chloroplast-targeted) were detected with rabbit anti-
His6 antiserum (GenScript, Piscataway, NY) and an
alkaline phosphatase-conjugated goat anti-rabbit sec-
ondary antibody (Jackson ImmunoResearch Europe
Ltd., Suffolk, UK) both diluted 1:5000 in PBS. BSA stand-
ard (NEB) at 900, 600, 300 and 150 ng was used for com-
parative densitometric quantification of purified PfGAP50.
The evaluation was performed using AIDA software
(Raytest, Straubenhardt, Germany).
Rabbit immunization, titer determination and IgG
purification
Rabbits were housed, immunized and sampled by Bio-
genes GmbH (Berlin, Germany), according to national
animal welfare regulations. The animal facilities and pro-
tocols were reviewed and approved by: Landesamt für
Landwirtschaft, Lebensmittelsicherheit und Fischerei
MecklenburgVorpommern (LALLF M-V) (Approval No:
7221.3-2-030-13). To isolate the blood after immunization
according to national regulations the animals were anes-
thetized using Ventranquil, stunned using a captive bolt
device and exsanguinated by throat cut. Two rabbits were
hyper immunized intramuscularly with the plant-derived
and purified PfGAP50-cTPH formulated with a propri-
etary Biogenes adjuvant (an oil in water emulsion contain-
ing lipopolysaccharides) on days 0, 7, 14, 28, 49 and 77.
200 μg of antigen were used for prime and 100 μg for the
five consecutive boosts. Serum samples were taken on
days 35, 63 and 91. For titer determination, the samples
from the three bleeds, as well as pre-immune serum, were
tested for reactivity with the plant-derived PfGAP50-cTPH
by enzyme-linked immunosorbent assay. Titer determin-
ation and IgG purification by Protein A was performed as
previously described [28]. End-point titers were deter-
mined as the highest dilution that gave the double the
value of the background (day 0, pre-immune serum).
Immunofluorescence assay (IFA)
IFAs were carried out on three different P. falciparum
stages (schizonts, mature gametocytes, and macroga-
metes) by immunolabeling with 10 μg/mL purified
PfGAP50-cTPH-specific rabbit IgG (day 63) or 10 μg/mL
IgG purified from normal rabbit serum as previously de-
scribed [33]. The sexual stages were co-labeled with anti-
bodies against PfMsp1 (schizonts) or Pfs25 (mature
gametocytes and macrogametes).
Zygote inhibition assay (ZIA)
The zygote inhibition potential of the PfGAP50-
cTPH antisera was investigated by zygote inhibition
assay (ZIA) as described in detail by Simon et al.
[24]. PfGAP50-cTPH-specific rabbit immune IgG
purified from day 63 and day 91 were used at con-
centrations of 1 mg/mL in the final assay volume.
The numbers of zygotes were counted in triplicate
using a hemocytometer.
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Additional file
Additional file 1: SDS-PAGE based quantification (densitometric
against a BSA standard) of PfGAP50 variants in IMAC elution
fractions (three independent replicate each). Mock purification of wt
N. benthamiana extract was included. Proteins were eluted from the
IMAC column using three elution steps (elution 1 (E1): 10 mM imidazole;
elution 2 (E2): 100 mM imidazole and elution 3 (E3): 250 mM imidazole).
6 μl of each sample was loaded under reducing conditions. 1: 150 ng
BSA/slot; 2: 300 ng BSA/slot; 3: 600 ng BSA/slot; 4: 900 ng BSA/slot; 5–7:
E1-3 from mock purification; 8–10: E1-3 from PfGAP50-ERH repeat 1;
11–13: E1-3 from PfGAP50-ERH repeat 2; 14–16: E1-3 from PfGAP50-ERH repeat
3; 17–19: E1-3 from PfGAP50-cTPH repeat 1; 20–22: E1-3 from PfGAP50-cTPH
repeat 2; 23–25: E1-3 from PfGAP50-cTPH repeat 3. (PDF 156 kb)
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